Cargando…

CXCR5(+)CD8 T cells: Potential immunotherapy targets or drivers of immune-mediated adverse events?

CXCR5(+)CD8 T cells have attracted significant interest within multiple areas of immunology, cancer, and infection. This is in part due to their apparent dual functionality. These cells perform as cytotoxic cells in a variety of infection states including LCMV, HBV, HIV and SIV. However, CXCR5(+)CD8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turner, Christi N., Mullins, Genevieve N., Hoyer, Katrina K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606409/ https://www.ncbi.nlm.nih.gov/pubmed/36314014 http://dx.doi.org/10.3389/fmed.2022.1034764

Ejemplares similares

CXCR5+ CD8 T Cells: Protective or Pathogenic?
por: Valentine, Kristen M., et al.
Publicado: (2019)

Characteristics of dust mite sublingual immunotherapy-associated adverse events in the early phase
por: Chen, Ming, et al.
Publicado: (2022)

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
por: Nakamura, Yoshiyuki
Publicado: (2019)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
por: Kuo, Alyce M., et al.
Publicado: (2022)

Characteristics and Comparison of Adverse Events of Coronavirus Disease 2019 Vaccines Reported to the United States Vaccine Adverse Event Reporting System Between 14 December 2020 and 8 October 2021
por: Zou, Chenyu, et al.
Publicado: (2022)

Gastrointestinal adverse events of immunotherapy
por: Cappello, Giovanni, et al.
Publicado: (2021)

Immune Thrombocytopenia: A Rare Adverse Event of Vancomycin Therapy
por: Obi, Emeka S, et al.
Publicado: (2023)

Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
por: Riveiro-Barciela, Mar, et al.
Publicado: (2023)

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
por: Cardeña-Gutiérrez, Ana, et al.
Publicado: (2022)

Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management
por: Stucci, Stefania, et al.
Publicado: (2017)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
por: Albarrán-Artahona, Víctor, et al.
Publicado: (2022)

Immune-related adverse events of biological immunotherapies used in COVID-19
por: Baracaldo-Santamaría, Daniela, et al.
Publicado: (2022)

Adverse Events of Oncologic Immunotherapy and Their Management
por: Barber, Fedricker Diane
Publicado: (2019)

Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022)

The therapeutic effect of IL-21 combined with IFN-γ inducing CD4(+)CXCR5(+)CD57(+)T cells differentiation on hepatocellular carcinoma
por: Zhao, Changlin, et al.
Publicado: (2021)

Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy
por: Han, Zhi-Jian, et al.
Publicado: (2021)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Jing, Ying, et al.
Publicado: (2020)

T follicular helper cells: linking cancer immunotherapy and immune-related adverse events
por: Baumjohann, Dirk, et al.
Publicado: (2021)

The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
por: Coschi, Courtney H., et al.
Publicado: (2021)

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
por: Iranzo, Patricia, et al.
Publicado: (2022)

Multisystem immune-related adverse events due to toripalimab: Two cases-based review
por: Chen, Yanran, et al.
Publicado: (2022)

Rheumatological Adverse Events Following Immunotherapy for Cancer
por: Cretu, Ioana, et al.
Publicado: (2022)

Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors
por: Ding, Lizhong, et al.
Publicado: (2023)

Inflammation in the Pathogenesis of Arrhythmogenic Cardiomyopathy: Secondary Event or Active Driver?
por: Meraviglia, Viviana, et al.
Publicado: (2021)

The role of cardiac computed tomography in predicting adverse coronary events
por: Emfietzoglou, Maria, et al.
Publicado: (2022)

CD8(+)CXCR5(+) T Cells Regulate Pathology in the Genital Tract
por: Jiang, Janina, et al.
Publicado: (2013)

CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell
por: Wang, Binglin, et al.
Publicado: (2021)

CXCR3 Signaling in BRAF(WT) Melanoma Increases IL-8 Expression and Tumorigenicity
por: Jenkins, Molly H., et al.
Publicado: (2015)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6(+) CD8 T cells as a predictor of immune infiltration and immunotherapy outcomes in hepatocellular carcinoma
por: Li, Xiaogang, et al.
Publicado: (2023)

CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy
por: Pourchet, Aldo, et al.
Publicado: (2016)

Correction: T follicular helper cells: linking cancer immunotherapy and immune-related adverse events
Publicado: (2021)

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
por: Jing, Ying, et al.
Publicado: (2022)

CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways
por: Wein, Alexander N., et al.
Publicado: (2019)

Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Yu, Xiaolin, et al.
Publicado: (2021)

Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study
por: Gómez-Puerta, José A., et al.
Publicado: (2022)

Drug repositioning prediction for psoriasis using the adverse event reporting database
por: Ko, Minoh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jedv7idviptpcnuc9vnkrgfis4